Bioverse Episode 10 - Recap of ASCO2024 & BI02024

Event details

Speakers intro

Madeleine has over 16 years’ experience writing about the biopharma and medtech industries. She joined ApexOnco in 2023 after eight years at Evaluate Vantage, most recently as News Editor. Before that, she was Deputy Editor of Clinica, a medical device publication, and has also worked for Scrip as a reporter.

Ramon currently serves as VP, Head of Global Business Development and Strategic Collaborations with Seacross Pharmaceuticals USA Inc. where he is responsible for establishing strategic partnerships and collaborations with the pharmaceutical industry.  Prior to that he was the VP of BD for SystImmune where he led deal structuring and negotiations for the $8.4B global strategic collaboration between BMS and SystImmune for BL-B01D1.  With over 25 years of experience in the biotech pharma industry and having worked as a researcher for over 12 years, Ramon holds multiple patents in medical diagnostics and wearable electronic devices and excels in developing strategic partnerships with renowned institutions and pharmaceutical companies. Throughout his career, he has held key positions in biotech/pharma, drug discovery and development companies, contributing to their growth and success.  Prior to joining SystImmune, Ramon was the Head of Business Development at Conagen Pharmaceutical Division where he in-licensed a novel HER2 targeting antibody as well as an ADC platform for clinical development.  Prior to that, he was the Head of Corporate Development at AvantGen, Vice President of Corporate Development and Strategy at Zumutor Biologics, among others.  Ramon has Master of Science in Biology from California State University, was an NIH Research Fellow at the Department of Biochemistry, University of Oxford, U.K. and has succeeded the Effective Negotiations and Power of Persuasion Program from USC Marshall School of Business.

Angus Liu is a deputy editor at Fierce Pharma, the go-to destination for the news and trends shaping the pharma industry. He leads the publication’s oncology coverage.

Leon ‘Jun’ Tang, is the founding partner of InScienceWeTrust BioAdvisory, a business development company focused on the East-West cross-border partnerships in the pharmaceutical industry. Dr. Tang is also the founder of InScienceWeTrust Community, which has more than 2,000+ members from Asian biotech community. He is also the c-founder and host of Bioverse webinar.

Dr. Tang serves as a scientific advisor to Mianus Capital, a boutique US-based healthcare PE/VC fund currently focused on ophthalmology. He is also an advisor to BioSpark, an Asian biotech professional’s association based in Massachusetts.

Previously, Dr. Tang was a senior director of BD Search & Evaluation at Shanghai Henlius Biotech, a public biotech listed on Hong Kong Stock Exchange, a biotech sell-side analyst at Barclays Investment Bank, and a senior manager/senior analyst at the philanthropic venture fund of Cancer Research Institute of New York.

Dr. Tang has published 50+ academic papers, some of which are in Nature Reviews Drug Discovery, Lancet Oncology, Science Translational Medicine, Nature Communications, Science Advances, PNAS, etc. Dr. Tang received his bachelor’s degree from Tianjin University, master’s degree from Nankai University, PhD from Icahn School of Medicine of Mount Sinai, and postdoctoral training at Memorial Sloan Kettering Cancer Center. 

Organizer

Partner &Collaborators